These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28296283)

  • 1. Effects of Transendocardial CD34
    Bervar M; Kozelj M; Poglajen G; Sever M; Zemljic G; Frljak S; Cukjati M; Cernelc P; Haddad F; Vrtovec B
    Stem Cells Transl Med; 2017 Jun; 6(6):1515-1521. PubMed ID: 28296283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Repetitive Transendocardial CD34
    Vrtovec B; Poglajen G; Sever M; Zemljic G; Frljak S; Cerar A; Cukjati M; Jaklic M; Cernelc P; Haddad F; Wu JC
    Circ Res; 2018 Jul; 123(3):389-396. PubMed ID: 29880546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracoronary transplantation of CD34(+) cells is associated with improved myocardial perfusion in patients with nonischemic dilated cardiomyopathy.
    Lezaic L; Socan A; Poglajen G; Peitl PK; Sever M; Cukjati M; Cernelc P; Wu JC; Haddad F; Vrtovec B
    J Card Fail; 2015 Feb; 21(2):145-52. PubMed ID: 25459687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic Network and Response to Intramyocardial CD34+ Stem Cell Therapy in Patients With Dilated Cardiomyopathy.
    Haddad F; Sever M; Poglajen G; Lezaic L; Yang P; Maecker H; Davis M; Kuznetsova T; Wu JC; Vrtovec B
    J Card Fail; 2015 Jul; 21(7):572-82. PubMed ID: 25863169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy.
    Vrtovec B; Poglajen G; Lezaic L; Sever M; Socan A; Domanovic D; Cernelc P; Torre-Amione G; Haddad F; Wu JC
    Circulation; 2013 Sep; 128(11 Suppl 1):S42-9. PubMed ID: 24030420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intracoronary CD34+ stem cell transplantation in nonischemic dilated cardiomyopathy patients: 5-year follow-up.
    Vrtovec B; Poglajen G; Lezaic L; Sever M; Domanovic D; Cernelc P; Socan A; Schrepfer S; Torre-Amione G; Haddad F; Wu JC
    Circ Res; 2013 Jan; 112(1):165-73. PubMed ID: 23065358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of transendocardial CD34+ cell transplantation in patients with ischemic cardiomyopathy.
    Poglajen G; Sever M; Cukjati M; Cernelc P; Knezevic I; Zemljic G; Haddad F; Wu JC; Vrtovec B
    Circ Cardiovasc Interv; 2014 Aug; 7(4):552-9. PubMed ID: 25097199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD34
    Frljak S; Jaklic M; Zemljic G; Cerar A; Poglajen G; Vrtovec B
    Stem Cells Transl Med; 2018 Feb; 7(2):168-172. PubMed ID: 29380563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Electroanatomic Properties of the Myocardium Predict Response to CD34+ Cell Therapy in Patients With Ischemic and Nonischemic Heart Failure.
    Zemljic G; Poglajen G; Sever M; Cukjati M; Frljak S; Androcec V; Cernelc P; Haddad F; Vrtovec B
    J Card Fail; 2017 Feb; 23(2):153-160. PubMed ID: 27523610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of CD34+ Stem Cell Therapy in Nonischemic Dilated Cardiomyopathy Is Absent in Patients With Diabetes but Preserved in Patients With Insulin Resistance.
    Vrtovec B; Sever M; Jensterle M; Poglajen G; Janez A; Kravos N; Zemljic G; Cukjati M; Cernelc P; Haddad F; Wu JC; Jorde UP
    Stem Cells Transl Med; 2016 May; 5(5):632-8. PubMed ID: 27025690
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transendocardial CD34
    Žorž N; Poglajen G; Frljak S; Knezevič I; Vrtovec B
    Cell Transplant; 2022; 31():9636897221080384. PubMed ID: 35320035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Favorable Response to CD34+ Cell Therapy Is Associated with a Decrease of Galectin-3 Levels in Patients with Chronic Heart Failure.
    Poglajen G; Ksela J; Frljak S; Zemljic G; Boznar Alic E; Cerar A; Vrtovec B
    Dis Markers; 2019; 2019():8636930. PubMed ID: 31885743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effects of age, disease state, and granulocyte colony-stimulating factor on progenitor cell count and function in patients undergoing cell therapy for cardiac disease.
    Mozid AM; Jones D; Arnous S; Saunders N; Wragg A; Martin J; Agrawal S; Mathur A
    Stem Cells Dev; 2013 Jan; 22(2):216-23. PubMed ID: 22834565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Larger End-Diastolic Volume Associates With Response to Cell Therapy in Patients With Nonischemic Dilated Cardiomyopathy.
    Frljak S; Poglajen G; Zemljic G; Cerar A; Haddad F; Terzic A; Vrtovec B
    Mayo Clin Proc; 2020 Oct; 95(10):2125-2133. PubMed ID: 33012343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transendocardial CD34+ Cell Therapy does not Increase the Risk of Ventricular Arrhythmias in Patients with Chronic Heart Failure.
    Poglajen G; Zemljič G; Cerar A; Frljak S; Jaklič M; Androcec V; Vrtovec B
    Cell Transplant; 2019 Jul; 28(7):856-863. PubMed ID: 31046425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of combination cytokine and adult autologous bone marrow progenitor cell administration in patients with non-ischaemic dilated cardiomyopathy: the REGENERATE-DCM clinical trial.
    Hamshere S; Arnous S; Choudhury T; Choudry F; Mozid A; Yeo C; Barrett C; Saunders N; Gulati A; Knight C; Locca D; Davies C; Cowie MR; Prasad S; Parmar M; Agrawal S; Jones D; Martin J; McKenna W; Mathur A
    Eur Heart J; 2015 Nov; 36(44):3061-9. PubMed ID: 26333366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and Validation of an Automated Process for the Expansion of Peripheral Blood-Derived CD34
    Saucourt C; Vogt S; Merlin A; Valat C; Criquet A; Harmand L; Birebent B; Rouard H; Himmelspach C; Jeandidier É; Chartois-Leauté AG; Derenne S; Koehl L; Salem JE; Hulot JS; Tancredi C; Aries A; Judé S; Martel E; Richard S; Douay L; Hénon P
    Stem Cells Transl Med; 2019 Aug; 8(8):822-832. PubMed ID: 31037857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G-CSF mobilized peripheral blood stem cell collection for allogeneic transplantation in healthy donors: Analysis of factors affecting yield.
    Machaczka M; Hägglund H; Staver E; Joks M; Hassan M; Wahlin BE; Axdorph Nygell U
    J Clin Apher; 2017 Dec; 32(6):384-391. PubMed ID: 28101890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
    Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
    Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34(+) cell therapy is safe and effective in slowing the decline of hepatic reserve function in patients with decompensated liver cirrhosis.
    Nakamura T; Torimura T; Iwamoto H; Kurogi J; Inoue H; Hori Y; Sumie S; Fukushima N; Sakata M; Koga H; Abe M; Ikezono Y; Hashimoto O; Ueno T; Oho K; Okamura T; Okuda S; Kawamoto A; Ii M; Asahara T; Sata M
    J Gastroenterol Hepatol; 2014 Oct; 29(10):1830-8. PubMed ID: 24731186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.